Light at the End of the Shortage Tunnel
Patients struggling to fill prescriptions for popular GLP-1 receptor agonist drugs may finally see relief in the coming months. The FDA announced on April 1, 2026, that manufacturing expansions by both Novo Nordisk and Eli Lilly are on track to bring supply in line with demand by July or August 2026.
The shortage, which began in early 2024 as demand for weight loss and diabetes medications surged far beyond projections, has left millions of patients scrambling to find pharmacies with stock, resorting to compounding pharmacies, or going without their prescribed medications entirely.
Current Supply Status
According to the FDA's drug shortage database, updated March 31, 2026:
- Ozempic (semaglutide injection): Limited supply of 0.25mg and 0.5mg doses; 1mg and 2mg doses available
- Wegovy (semaglutide injection): All doses currently available in most markets
- Mounjaro (tirzepatide injection): Intermittent shortages of 2.5mg and 5mg starter doses
- Zepbound (tirzepatide for weight loss): Limited supply of all doses
"We are cautiously optimistic," said Dr. Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research. "The manufacturers have made enormous investments in production capacity, and we are seeing those investments begin to pay off."
Manufacturing Investments
Novo Nordisk has invested more than $18 billion in manufacturing expansion since 2023, including new production facilities in Denmark, France, and North Carolina. The company's Raleigh-area facility, which came online in January 2026, is expected to increase semaglutide production by 40%.
Eli Lilly has committed $12 billion to manufacturing, with its new facility in Lebanon, Indiana, now producing tirzepatide at scale. A second US facility in Concord, North Carolina, is expected to begin production in Q3 2026.
"The scale of investment in GLP-1 manufacturing is unprecedented in pharmaceutical history," said Geoffrey Porges, an analyst at Leerink Partners. "These companies are building capacity for a market they expect to grow to $150 billion annually by 2030."
The Compounding Pharmacy Question
The improving supply picture raises questions about the future of compounded semaglutide and tirzepatide. During the shortage, the FDA allowed compounding pharmacies to produce copies of the drugs under Section 503A of the Federal Food, Drug, and Cosmetic Act. Novo Nordisk and Eli Lilly have both filed lawsuits seeking to halt compounding operations.
If the FDA officially resolves the shortage designation, compounding pharmacies would be required to stop producing these medications. Patient advocacy groups have urged the FDA to maintain compounding access as a more affordable option, but the agency has signaled it will follow standard protocols.
What Patients Should Do Now
Healthcare providers recommend the following steps for patients currently on or seeking GLP-1 medications:
- Work with your pharmacy to set up automatic refill notifications
- Ask your provider about dose flexibility if your specific dose is unavailable
- Check the FDA shortage database regularly for updates
- Consider patient assistance programs offered by both manufacturers
- Do not stockpile medications, as this exacerbates supply issues
For patients currently using compounded versions, physicians recommend discussing a transition plan with their healthcare provider well before the shortage designation is officially lifted.
